Boston Scientific vs Intuitive Surgical
BSX and ISRG side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BSX and ISRG compare
Intuitive Surgical is the larger company, worth 2.5 times as much as Boston Scientific ($153B against $60.8B).
On earnings, Boston Scientific is cheaper: it trades at 17.0× trailing earnings, against 49.5× for Intuitive Surgical.
Intuitive Surgical grew revenue faster over the last twelve months (20.7% versus 13.5% for Boston Scientific).
Intuitive Surgical scores higher on the StockData Score (17 against 14 for Boston Scientific), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BSX | ISRG |
|---|---|---|
| Size and price | ||
| Market cap | $60.8B | $153B |
| Share price | $41.98 | $432.01 |
| Change, 1 year | −58.1% | −19.6% |
| Change, 5 years | −2.7% | 18.4% |
| Beta (5Y) | 0.77 | 1.33 |
| Employees | 59K | 17K |
| StockData Score | ||
| Total score | 14 | 17 (better) |
| Valuation score | 6 (better) | 2 |
| Growth score | 4 | 4 |
| Performance score | 1 | 5 (better) |
| Health score | 3 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 17.0× (better) | 49.5× |
| P/S | 2.9× (better) | 13.8× |
| P/B | 2.4× (better) | 8.4× |
| EV/EBITDA | 13.1× (better) | 42.7× |
| P/FCF | 16.8× (better) | 47.4× |
| PEG | 0.27 (better) | 1.70 |
| FCF yield | 6.0% (better) | 2.1% |
| Fair value | $93.08 | $350.05 |
| Margin of safety | 54.9% (better) | −23.4% |
| Growth | ||
| Revenue growth (TTM) | 13.5% | 20.7% (better) |
| Revenue growth, 5Y average | 15.2% | 18.2% (better) |
| Net income growth (TTM) | – | 20.4% |
| EPS growth (TTM) | 47.0% (better) | 21.8% |
| EPS growth, 5Y average | – | 21.8% |
| Profitability | ||
| Gross margin | 69.9% (better) | 66.7% |
| Operating margin | 19.8% | 31.3% (better) |
| Net margin | – | 28.4% |
| FCF margin | 17.3% | 29.2% (better) |
| Return on equity | – | 17.4% |
| Return on invested capital | 11.2% | 22.5% (better) |
| Financial health | ||
| Debt / equity | 0.51 (better) | 0.00 |
| Net debt / EBITDA | 2.17 | – |
| Interest coverage | 11.4× | – |
| Current ratio | 1.24 | 4.96 (better) |
| Altman Z-score | 2.87 | 37.48 (better) |
| Piotroski F-score | – | 6 |
| Dividends and buybacks | ||
| Buyback yield | – | 2.3% |
| Shareholder yield | 0.00% | 2.3% (better) |
| Ownership | ||
| Held by institutions | 92.1% | 86.9% |
| Held by insiders | 0.19% | 0.47% |
| Insider net buying, 12 months | −$13.0M (better) | −$57.3M |
| Superinvestors holding | 1 | 2 (better) |
| Short interest, % of float | 2.9% | 2.1% |
Go deeper
- BSX stock overview
- BSX income statement
- BSX valuation and score
- ISRG stock overview
- ISRG income statement
- ISRG valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.